Clinical Outcomes in WHO Type I Anovulatory Women Using r-hFSH+r-hLH in a 2:1 Ratio or hMG-HP

NCT01623570 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Hypogonadotropic Hypogonadism

Interventions

DRUG: Pergoveris: 150IU r-hFSH + 75IU r-hLH
DRUG: Menopur: HMG-HP (150 IU)

Sponsor

Centro Riproduzione e Andrologia